Sparsentan - Travere Therapeutics
Alternative Names: DARA; FILSPARI; PS-433540; RE-021Latest Information Update: 28 May 2025
At a glance
- Originator Bristol-Myers Squibb
- Developer CSL Vifor; Renalys Pharma; Retrophin; Travere Therapeutics
- Class Anti-inflammatories; Antihypertensives; Isoxazoles; Nerve growth factors; Small molecules; Spiro compounds; Sulfonamides; Urologics; Vascular disorder therapies
- Mechanism of Action Angiotensin type 2 receptor antagonists; Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed IgA nephropathy
- Preregistration Focal segmental glomerulosclerosis
- Phase II Anti-neutrophil cytoplasmic antibody-associated vasculitis; Hereditary nephritis; Vasculitis
- Discontinued Hypertension
Most Recent Events
- 28 May 2025 Travere Therapeutics announces intention to hold an advisory committee meeting with the US FDA to discuss the application
- 23 May 2025 CSL Vifor plans to launch Sparsentan in IgA nephropathy in United Kingdom (PO), in the second half of 2025
- 23 May 2025 National Institute for Health and Care Excellence (NICE) recommends sparsentan for IgA nephropathy in England